Premium
Cisplatin‐induced renal effects and thromboxane A 2 receptor blockade
Author(s) -
DORNER G. T.,
PEHAMBERGER H.,
KORNEK G.,
STEGER G.,
MÜLLER M.,
WOLZT M.,
KLETTER K.,
JAMES P.,
BREITENEDER H.,
EICHLER H. G.,
BLÖCHLDAUM B.
Publication year - 1997
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1046/j.1365-2362.1997.2060753.x
Subject(s) - renal function , cisplatin , nephrotoxicity , medicine , urology , renal blood flow , thromboxane , effective renal plasma flow , filtration fraction , placebo , antagonist , kidney , thromboxane b2 , chemotherapy , endocrinology , receptor , platelet , pathology , alternative medicine
The aim of this study was to evaluate the renal protective effect of linotroban, a thromboxane A 2 receptor antagonist, in 25 patients with malignant tumours scheduled for cisplatin therapy. Cisplatin was administered 1 h after the start of a 24‐h continuous infusion of linotroban or placebo. Glomerular filtration rate and effective renal plasma flow were measured. Infusions of cisplatin decreased glomerular filtration rate by 17 ± 25 mL min −1 ( P = 0.049 vs. baseline) and effective renal plasma flow by 94 ± 150 mL min −1 ( P = 0.049 vs. baseline) in the placebo group. In the linotroban group a decrease in glomerular filtration rate by 11 ± 18 mL min −1 ( P = 0.050 vs. baseline) and in effective renal plasma flow by 26 ± 63 mL min −1 ( P = 0.2 vs. baseline) was noted. However, no difference was noted between groups in response to treatment. Our findings indicate that linotroban may not be useful for prevention of cisplatin's acute nephrotoxic effects.